Authors
Jothydev Kesavadev, MD, FRCP(London), FRCP(Glasg), FACP, FRSSDI, Chairman & Managing Director, Jothydev’s Diabetes Research Centers, Trivandrum & Kochi; Gopika Krishnan, GRBPharm, MSc, MBA, Academic Head, Jothydev’s Diabetes Research Center, Trivandrum
Abstract
Introduction: Insulin pumps, in use for over 50 years, have significantly advanced. Modern models provide continuous subcutaneous insulin delivery, wirelessly integrate with continuous glucose monitors, and employ sophisticated control algorithms for automated insulin delivery and hypoglycemia prevention.
Physiological Benefits: Variable basal rates and diverse bolus delivery options enable near-physiological insulin delivery, reducing glucose variability. This contributes to multiple pleotropic benefits, including the disappearance of peripheral neuropathic pain, improved sexual function, relief from angina pain, and enhanced quality of life.
Technological Advancements: Rapid advancements in technology and newer rapid-acting insulins are continuously improving pump design and function. The first-generation artificial pancreas, 640G, is already available in the global market, including India.
Indian Context: This review specifically shares the authors’ clinical experience and Indian evidence regarding the use of insulin pumps in both type 1 and type 2 diabetes over a 12-year period.